Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

Fig. 5

Comparison of treatment outcomes of D2T RA by treatment types. Changes in CDAI and HAQ-DI over the course of a year are compared using panel data analysis and IPTW among D2T RA. TNFi is treated as the reference. *p < 0.05. CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment Questionnaire Disability Index; IPTW, propensity-based inverse-probability treatment weighted; D2T RA, difficult-to-treat rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; IL-6Ri, interleukin-6 receptor inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte–associated antigen-4 immunoglobulin; JAKi, Janus kinase inhibitor

Back to article page